Main baseline characteristics of HCM population
| Total (n=383) | |
|---|---|
| Clinical and demographic | |
| Age (years) | 51±16 |
| Male sex, n (%) | 254 (59) |
| NYHA III-IV, n (%) | 56 (15) |
| Echocardiography | |
| IVS (mm) | 17.7±5.1 |
| PW (mm) | 12.1±3.1 |
| RWT | 0.74±0.2 |
| LVEF (%) | 69±8 |
| Resting LV gradient >30 mm Hg, n (%) | 138 (35) |
| Restrictive filling pattern, n (%) | 14 (4) |
| Moderate-to-severe MR, n (%) | 24 (6) |
| Medications | |
| Beta-blockers, n (%) | 218 (52) |
| Calcium channel blockers, n (%) | 86 (21) |
| ACE inhibitors, n (%) | 65 (16) |
| Diuretics, n (%) | 50 (13) |
| Antiarrhythmic therapy, n (%) | 17 (5) |
| ICD, n (%) | 120 (31) |
ACE, angiotensin converting enzyme; EF, ejection fraction; HCM, hypertrophic cardiomyopathy; ICD, implantable cardioverter defibrillator; IVS, interventricular septum; LAVi, left atrium volume index; LV, left ventricle; LVEF, left ventricle ejection fraction; MR, mitral regurgitation; PW, posterior wall; RAVi, right atrium volume index; RV, right ventricle; RVSP, right ventricle systolic pressure; RWT, relative wall thickness.